In a large-scale analysis, researchers determined whether endovascular mechanical thrombectomy is a safe and effective therapy for acute ischemic stroke during pregnancy and the postpartum period.
Endovascular treatment alone is neither superior nor noninferior to intravenous alteplase followed by EVT in a cohort of European patients with stroke.
Researchers at AHA 2021 presented their findings from a study that compared CVD risk factors and in-hospital outcomes in young, Black US adults a decade apart.
In an observational study, researchers assessed outcomes from mobile stroke units or emergency medical services within 4.5 hours after onset of acute stroke symptoms.
Researchers examined the 4-year outcomes of the PRAGUE-17 trial, which compared the effectiveness of LAA closure against NOACs for preventing cardioembolic events in AF.
In a Cochrane Review update, researchers sought to assess the effectiveness and safety of early anticoagulation for people with acute presumed or confirmed ischemic stroke.
For patients with LVO stroke not treated with reperfusion, symmetric collateral pattern at CTA is highly specific for small 24-hour ischemic core volume.
![Decisions regarding thromboprophylaxis requires weighing the risk of stroke against the risk of bleeding in each patient.[3,4] Numerous risk assessment tools are available, including CHADS2, CHA2DS2-VASc, and HAS-BLED. American and European guidelines recommend the use of CHA2DS2-VASc, which considers sex, age, and history of congestive HF, hypertension, stroke/transient ischemic attack/thromboembolism, vascular disease, and diabetes mellitus.[3,4] Compared with other stroke risk assessment measures, this tool performed best in identifying patients at low risk of stroke who did not require anticoagulation therapy.[12] Oral anticoagulation is recommended in any patient with a score ≥2 on the CHA2DS2-VASc. In these patients, warfarin or the novel anticoagulants dabigatran, rivaroxaban, apixaban, or edoxaban can be considered, except in the setting of moderate to severe chronic kidney disease, where reduced doses of direct thrombin or factor Xa inhibitors are preferable.[4]](https://www.neurologyadvisor.com/wp-content/uploads/sites/10/2021/11/slideshowsizeatrialfibrillati_1061315.jpg)
